| Category | Min Lots | Shares | Amount |
|---|---|---|---|
| Retail (sNII) | 2 | 800 | ₹2,74,400 |
| HNI / NII | 3 | 1200 | ₹4,11,600 |
| Category | Sub (×) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | 50.22× | 29,69,200 | 14,91,16,800 | ₹101.84 Cr |
| NII / HNI (Total) | 146.91× | 8,91,600 | 13,09,81,200 | ₹30.58 Cr |
| Retail Investors | 70.27× | 20,79,200 | 14,61,12,800 | ₹71.32 Cr |
| Total ** | 71.75× | 59,40,000 | 42,62,10,800 | ₹203.74 Cr |
| Market Maker * | 1× | 3,13,200 | 3,13,200 | ₹10.74 |
| Metric | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Revenue | 236.50 | 322.58 | 206.45 |
| PAT | 38.69 | 28.13 | 34.44 |
| EBITDA | 64.23 | 71.32 | 37.63 |
| Net Worth | -0.04 | 189.95 | 161.81 |
| Total Assets | 561.34 | 455.49 | 339.25 |
| Reserves | 21288920.00 | 188.37 | 160.24 |
| Borrowings | 243.85 | 164.95 | 96.91 |
Incorporated in 2010, Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing a diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, and distribution/supply of diagnostic equipment for different diagnostic healthcare needs.
The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges.
The company's key manufacturing segments include indigenous manufacturing of reagents (Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and Others [POC Devices & Rapid Tests]) and supplying/manufacturing of in-vitro diagnostics (IVD) and Pathology equipment & devices.
As of December 31, 2025, the total annual capacity was about 1.4 million kits (Haematology, Clinical Chemistry, Rapid/Elisa) and 1,200 Selectra Machines.
As of March 31, 2026, the manufacturing teams include 126 employees and 223 third-party workers collaborating with R&D, supply chain, and external partners to meet benchmarks.
Competitive Strengths: